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ABSTRACT
Although radiotherapy is often used to treat localized disease and for palliative 
care in prostate cancer patients, novel methods are required to improve the sensitivity 
of aggressive disease to ionizing radiation. AMP-activated protein kinase (AMPK) is 
an energy sensor which regulates proliferation, aggressiveness and survival of cancer 
cells. We assessed the ability of the AMPK activator 5-aminoimidazole-4-carboxamide-
1-β-D-ribofuranoside (AICAR) to sensitize prostate cancer cells to radiation. Prostate 
cancer cell lines LNCaP and PC3 were treated with X-rays and AICAR then assessed 
for clonogenic survival, spheroid growth delay, cell cycle progression, and AMPK 
and p53 activity. AICAR synergistically enhanced the clonogenic killing capacity, 
spheroid growth inhibition and pro-apoptotic effect of X-rays. The mechanism of 
radiosensitization appeared to involve cell cycle regulation, but not oxidative stress. 
Moreover, it was not dependent on p53 status. Treatment of PC3 cells with a fatty 
acid synthase inhibitor further enhanced clonogenic killing of the combination of 
X-rays and AICAR, whereas mTOR inhibition caused no additional enhancement. These 
results indicate that interference with metabolic signalling pathways which protect 
cells against irradiation have the potential to enhance radiotherapy. Activation of 
AMPK in combination with radiotherapy has the potential to target metabolically 
active and aggressive tumors which are currently untreatable.
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INTRODUCTION
Prostate cancer is the most commonly diagnosed 
cancer amongst men and the second most common 
cause of cancer death in men [1]. It is a disease that 
predominantly affects men over the age of 50 and its 
incidence is expected to increase. Although radiotherapy 
is often used for control of localized disease and palliation, 
resistance is common and there is no effective treatment 
for disseminated disease [2]. Treatment options for patients 
with metastatic, relapsing and castration-resistant disease 
are currently limited to hormonal manipulation and radical 
prostatectomy. Therefore, new strategies which exploit the 
inherent differences between tumors and normal cells are 
required to sensitize tumors to radiation [3].
A hallmark of malignancy is abnormal metabolism 
which generates biomass and energy for proliferation, 
migration and cell signalling. This metabolic adaption 
by cancer cells also confers survival advantages to these 
cells and contributes to resistance to therapy [4]. Increased 
lipogenesis is observed in prostate cancer cells and is 
associated with their rapid growth and aggressiveness 
and inhibitors of fatty acid synthase (FASN) reduce 
cancer cell proliferation [5, 6]. Compared with their 
radiosensitive counterparts, radioresistant cancer cells also 
have altered components of energy metabolism, including 
elevated levels and activity of FASN [7, 8]. Furthermore, 
in response to exposure to ionizing radiation, metabolic 
regulators such as 5’ adenosine monophosphate-activated 
protein kinase (AMPK) are activated [9].
AMPK, a signalling protein activated by energetic 
stress, is a key energy-sensor whose activation by 
increased AMP:ATP ratios leads to restoration of energy 
homeostasis by switching on catabolic pathways thereby 
generating ATP, while switching off ATP-consuming 
processes [10]. As these anabolic pathways include cell 
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growth and proliferation, there exists a possibility that 
activation of AMPK may be beneficial in cancer therapy. 
Indeed, it has been demonstrated that activation of AMPK 
by the AMP analog 5-aminoimidazole-4-carboxamide-1-
β-D-ribofuranoside (AICAR) inhibited growth of prostate 
cancer cells [11]. Importantly, the increase in apoptosis 
and reduction in cell viability and proliferation observed in 
cancer cells treated with AICAR were not observed in non-
cancer cells, indicating that this drug exhibits preferential 
toxicity for cancer cells [12–14]. AICAR is a cell-
permeable nucleoside which is converted intracellularly 
by adenosine kinase to AICAR monophosphate which 
binds the regulatory γ subunit to activate AMPK. Novel 
drugs which directly activate AMPK also decreased 
proliferation, increased apoptosis of cancer cells 
and inhibited tumor growth in animal models [15]. 
Furthermore, drugs which act indirectly to activate AMPK, 
including metformin, aspirin and FASN inhibitors, have 
also been demonstrated to decrease proliferation of cancer 
cells [6, 16–18] and potentially sensitize cancer cells to 
radiation [8, 9, 19, 20]. The anti-tumor effect of activation 
of AMPK has been postulated to occur through several 
distinct mechanisms, including inhibition of two major 
drivers of prostate cancer carcinogenesis, lipogenesis 
and the mTOR signalling pathway [21, 22], indicating 
that AMPK activators may offer an advantage over drugs 
targeting only one anti-tumor pathway. Therefore, our aim 
was to evaluate the potential radiosensitizing effect of 
AMPK activation on prostate cancer cells and determine 
possible mechanisms of interaction.
RESULTS
AMPK activation is toxic to prostate cancer cells
AMPK activation by AICAR (0.5 to 3 mM) was 
manifest in LNCaP cells and PC3 cells by phosphorylation 
of acetyl Co-A carboxylase (ACC), a downstream 
target of AMPK (Figure 1A). Using the MTT assay to 
determine toxicity of AICAR to PC3 and LNCaP cells 
in monolayer cultures, it was observed that AICAR 
caused a concentration-dependent decrease in survival 
after treatment for 24 h (Figure 1B). AICAR was 
significantly more toxic to PC3 cells than LNCaP cells at 
concentrations of 0.5 and 1 mM. No further increase in 
cell kill resulted from treatment of PC3 cells with 3 mM 
AICAR, whereas LNCaP cells succumbed in a manner 
similar to that observed for PC3 cells. AICAR also 
induced a concentration-dependent decrease in survival 
of PC3 clonogens 24 h after administration (Figure 1C). 
The IC50 value was 1 mM. Simultaneous administration 
of AICAR with the antioxidant N-acetyl cysteine (NAC) 
indicated that the clonogenic kill caused by AICAR in PC3 
cells was not dependent on oxidative stress (Figure 1D). 
Unlike PC3, LNCaP cells did not form clonogens, and 
so the effects of AICAR on these cells was assessed in 
spheroid growth assays. Conversely, PC3 cells do not form 
spheroids. As a single agent, AICAR also reduced growth 
of spheroids composed of LNCaP cells in a concentration-
dependent manner (Figure 1E). Although the shape of 
the concentration-effect graph is similar to that of PC3 
clonogenic survival, a higher concentration of AICAR was 
required in spheroids.
AICAR sensitized prostate cancer cells to 
X-radiation
A comparison of the potency of alternative 
schedules of administration of the modalities AICAR 
and X-rays revealed that the most effective kill of 
PC3 clonogens was achieved when treatments were 
administered simultaneously (Figure 2A). Therefore, all 
further experiments utilized this administration schedule. 
After simultaneous administration, AICAR enhanced the 
clonogenic kill of PC3 cells induced by a range of doses 
(1 to 4 Gy) of radiation (Figure 2B). The surviving 
fractions following radiation treatment at a dose of 2 Gy 
(SF2) were 0.45 ± 0.03, 0.30 ± 0.02 and 0.25 ± 0.04 
for 0, 0.5 and 1 mM AICAR, respectively, giving dose 
enhancement ratios (DER) of 1.86 ± 0.15 and 2.09 ± 0.31 
for 0.5 and 1 mM AICAR, respectively. Moreover, 
combination index analysis (Figure 2C) indicated that 
at all toxicity levels, the combination of AICAR and 
radiation resulted in a greater than additive enhancement 
of clonogenic kill of PC3 cells, indicated by CI values less 
than 1. The anti-diabetic drug metformin may sensitize 
cells to radiation by acting as an AMPK activator. We 
observed that the enhancing effect of 0.5 mM AICAR 
on clonogenic killing activity of radiation was similar to 
that of 5 mM metformin (Figure 2D). The percentage of 
propidium iodide-stained cells in sub-G1, characteristic of 
apoptosis, was increased by radiation (2 Gy X-rays) and 
in a concentration-dependent manner by AICAR (Figure 
2E and 2F). Furthermore, the pro-apoptotic effect of 
single agents was enhanced in both LNCaP and PC3 cells 
by the simultaneous administration of the combination of 
treatments. Growth of multicellular spheroids composed 
of LNCaP cells was delayed by irradiation (Figure 3). 
Radiation-induced growth delay was enhanced by the 
simultaneous administration of 5 mM AICAR (Figure 
3A). On the basis of AUC values (Figure 3B), the 
combination of radiation treatment and AICAR resulted in 
greater than additive inhibition of growth. The inhibition 
of spheroid growth can be observed in representative 
images of spheroids at the end of the experiment in Figure 
3C. The activation of AMPK by AICAR in LNCaP cells, 
indicated by phosphorylation of ACC, was unaffected by 
administration of 2 Gy X-rays (Figure 3D).
Effect of AICAR on cell cycle progression
The effect of a range of concentrations of AICAR 
on the cell cycle distribution of asynchronously growing 
PC3 and LNCaP cells is shown in Figure 4A. AICAR had 
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no significant effect on cell cycle progression 6 h after 
the initiation of treatment. The effect of AICAR on p53 
was also determined 6 h after treatment (Figure 4B). 
Expression of total or phosphorylated p53 in LNCaP cells 
was not affected by AICAR. Expression of p21 was used 
as a marker of p53 transcriptional activity. The failure to 
increase expression in LNCaP cells indicated no change 
in p53 activation by AICAR. Expression of p53 (total and 
phosphorylated) and p21 was not detected in PC3 cells 
with or without AICAR treatment.
Irradiation of LNCaP cells induced the expression 
of p21 after 3 and 6 h administration (Figure 5A). In both 
LNCaP and PC3 cell lines, radiation alone caused a rise in 
the G2/M population 6 hours after irradiation (Figure 5B 
and 5C). Although AICAR alone had no significant 
effect on cell cycle, simultaneous administration of 
AICAR significantly reduced the radiation-induced cell 
cycle arrest: the percentage of cells in G2/M was similar 
to those of untreated control cells. Activation of p53, as 
indicated by phosphorylation of p53 and expression of 
p21, was observed in LNCaP in response to irradiation 
(2 Gy X-rays), whereas p53 was not detected in PC3 
cells (untreated or irradiated) (Figure 5D). The radiation-
induced p53 activation and p21 expression observed in 
LNCaP cells was not affected by the co-administration of 
AICAR (1 mM). LNCaP cells which had been irradiated 
24 h before fixing and staining with propidium iodide 
had an increased proportion of cells in G1 phase of the 
cell cycle (Figure 5E). This radiation-induced cell cycle 
arrest was prevented by simultaneous administration of 
AICAR (1 and 3 mM). In contrast, in PC3 cells there was 
no significant arrest in G1 cells 24 h after irradiation, and 
AICAR had no effect on cell cycle (Figure 5F).
Enhancement of AICAR radiosensitization
Inhibition of mTOR using everolimus (0.3 µM) 
enhanced the radiation-induced clonogenic kill of PC3 cells 
Figure 1: The cytotoxic effect of AICAR as a single agent on LNCaP and PC3 cells. (A) Expression of phosphorylated 
acetyl Co-A carboxylase (P-ACC) in LNCaP cells 6 h and PC3 cells 24 h after administration. Average fold change in expression relative 
to control is shown under blot, mean of 3 separate experiments. β-actin is used as a loading control. (B) MTT assay of PC3 (white bars) 
and LNCaP (black bars) cells 24 h after administration of AICAR. (C) Clonogenic survival of PC3 cells treated with AICAR for 24 h. 
(D) Clonogenic assay was also carried out in the absence (white bars) and presence (black bars) of NAC (1 mM), which was co-incubated 
with AICAR for 24 h. (E) Growth of spheroids composed of LNCaP cells was measured for 21 days after administration of AICAR for 
24 h. Graph shows the area under the V/V0 curve. Data are means ± SEM, n = 3. 
*p < 0.05 and **p < 0.01 compared to untreated controls, 
†p < 0.05, ††p < 0.01 and ns = not significant compared to other cell line treated with same concentration of AICAR.
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Figure 2: AICAR sensitizes PC3 cells to experimental radiotherapy. (A) The effect of administration schedule of the combination 
of AICAR (1 mM) and x-radiation (2 Gy) on the kill of PC3 clonogens was tested using 3 administration schedules (i) radiation and drug 
administered simultaneously, (ii) radiation administered 24 h before drug, (iii) radiation administered 24 h after drug. (B) Radiation kill 
curves of PC3 cells exposed to AICAR (0.5 or 1 mM) and x-radiation at a range of doses, administered simultaneously. (C) The effect of 
treatment of PC3 cells with AICAR and x-radiation on combination indices. CI values are mean ± SEM of 3 experiments. EDx = dose 
required to kill x% of clonogens. (D) The effect of AICAR (0.5 mM) or metformin (5 mM) on clonogenic survival of PC3 cells exposed 
to 0 or 2 Gy x-irradiation. Effect of single agents and combination treatments on apoptosis (% of propidium iodide-stained cells in sub-G1 
phase) 24 h after simultaneous administration of AICAR and radiation (2 Gy X-rays) on (E) LNCaP and (F) PC3 cells. Data are means ± 
SEM, n = 3. *p < 0.05 and **p < 0.01 compared to untreated controls, †p < 0.05 and ††p < 0.01 compared to radiation treatment alone.
Figure 3: Combination of AICAR and ionizing radiation in LNCaP cells. Growth of spheroids composed of LNCaP cells 
after simultaneous administration of AICAR (5 mM) and x-radiation (2 Gy). Data is presented as (A) relative spheroid volume over 
21 days and (B) area under the V/V0 curve relative to untreated control spheroids. Data are means ± SEM, n = 3. *p < 0.05 compared 
to untreated controls, †p < 0.05 compared to radiation treatment alone. (C) Representative images of spheroids 21 days after treatment. 
(D) Representative blot of the effect of X-rays (2 Gy) and AICAR (1 mM) on phosphorylation of ACC. Average fold change in expression 
relative to control is shown under blot, mean of 3 separate experiments. β-actin is used as a loading control.
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(Figure 6A). However, the co-administration of everolimus 
and AICAR (0.5 mM) did not significantly increase the 
clonogenic killing capacity of either agent alone. A triple 
combination of AICAR, everolimus and X-rays also did 
not significantly increase the clonogenic kill observed. 
Conversely, the fatty acid synthase inhibitor C75 enhanced 
both the radiation-induced and AICAR-induced clonogenic 
kill of PC3 cells (Figure 6B). Furthermore, a triple 
combination consisting of C75, AICAR and X-rays had 
greater clonogenic killing potency than any of the single 
agents or double combinations (p < 0.01).
DISCUSSION
The AMPK signalling pathway regulates cellular 
energy processes and is activated during stress conditions. 
Figure 4: Cell cycle analysis and effect on p53 activity of LNCaP and PC3 cells after treatment with AICAR. (A) Cell 
cycle distribution of LNCaP and PC3 cells after 6 h treatment of cells with AICAR. Data are means ± SEM, n = 3 (LNCaP cells) and 
n = 4 (PC3 cells). (B) Expression of total p53, phosphorylated p53 (serine 15) and p21 in LNCaP and PC3 cells 6 h after treatment. Positive 
control is LNCaP cells 6 h after irradiation (2 Gy), β-actin is used as a loading control.
Figure 5: Cell cycle analysis and effect on p53 activity of LNCaP and PC3 cells after combination treatment with 
AICAR and X-rays. (A) p21 expression in LNCaP cells 1, 3 and 6 h after irradiation (2 Gy X-rays). Cell cycle analysis after treatment 
of (B) LNCaP cells and (C) PC3 cells with radiation and AICAR, alone or in combination. Graphs show proportion of cells in G2/M phase 
of cell cycle 6 h after administration of treatments. (D) Total p53, phosphorylated p53 (serine 15) and p21 expression was determined in 
LNCaP and PC3 cells 6 h after administration of radiation (2 Gy X-rays) or AICAR (1 mM) or combinations of both treatments. β-actin 
is used as a loading control. (E) LNCaP cells and (F) PC3 cells in G1 phase of cell cycle 24 h after administration of treatments. Data are 
means ± SEM, n = 3 (LNCaP cells) and n = 4 (PC3 cells). *p < 0.05 and **p < 0.01 compared to untreated controls, †p < 0.05 and ††p < 0.01 
compared to radiation treatment alone.
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AMPK is a mediator of tumor suppressor pathways and 
its activation can inhibit the growth of prostate cancer 
cells [11]. Ionizing radiation may also activate AMPK 
[9], contributing to its pro-apoptotic and anti-proliferative 
effect. Furthermore, high expression of AMPKα may 
associate with improved prognosis [23]. Here, we 
investigated the radiosensitizing potential of the AMPK 
activating drug AICAR and compared the response of two 
prostate cancer cell lines.
The cytotoxicity of AICAR was apparent in two 
prostate cell lines, PC3 and LNCaP, in two in vitro 
models of tumor growth, clonogenic assays using 
2-dimensional cultures and multicellular tumor spheroids 
using 3-dimensional cultures. The observed cytotoxic 
and growth inhibitory effects of AICAR occurred at 
concentrations which increased phosphorylation of 
acetyl Co-A carboxylase (ACC), indicating that these 
concentrations of AICAR were sufficient to activate 
AMPK. The cytotoxicity of many anti-cancer drugs 
is mediated directly or indirectly by the induction of 
oxidative stress [24]. Oxidative stress activates AMPK 
in order to maintain the redox balance of cells [25]. 
Intriguingly, Kuznetsov et al. [26] observed that, although 
AICAR alone not induce the generation of reactive oxygen 
species, the antioxidant NAC decreased, but did not 
prevent, AICAR-induced apoptosis of acute lymphoblastic 
leukaemia cells 48 h after co-administration. However, we 
observed that NAC did not prevent the AICAR-induced 
cytotoxicity of PC3 cells 24 h after administration, 
indicating that the cytotoxic activity of AICAR is not 
mediated by oxidative stress.
The biguanide drug metformin has anti-tumor 
activity [21] and patients taking this drug to treat their 
type 2 diabetes may have a reduced risk of certain cancers 
[27], including prostate cancer [28]. Although the cancer 
killing effect of metformin has been attributed to the 
indirect activation of AMPK [29], anti-proliferative effects 
of metformin in LNCaP cells have also been proposed to 
occur in an AMPK-independent manner [30]. We observed 
here that, in addition to decreasing survival of clonogens 
of PC3 prostate cancer cells, metformin enhanced the 
clonogenic killing activity of ionizing radiation. This is in 
agreement with previous studies of metformin combined 
with ionizing radiation [9, 23], which was demonstrated 
to be dependent on AMPK activation in pancreatic cancer 
cells [19]. However, the concentrations of metformin 
used experimentally varies greatly and concentrations 
required for AMPK activation, anti-proliferative effects 
and radiosensitization demonstrated here and previously 
[23, 30, 31] may be 1–2 orders of magnitude higher than 
those estimated to occur in human plasma following 
therapeutic doses [17]. Furthermore, the radiosensitizing 
effect of metformin appears to be cell line dependent and 
was not always greater than an additive affect [9, 23, 32]. 
Zanella et al. [31] also suggested that the sensitizing 
effect of metformin with radiotherapy in vivo could be 
caused by re-oxygenation of radio-resistant hypoxic 
cells rather than an effect on tumor cell radiosensitivity. 
Here, we calculated dose enhancement ratios (DER) of 
AICAR from clonogenic assays, and the values obtained 
indicated a synergistic interaction [33]. The combination 
index analysis method was also utilized to determine 
interaction between therapeutic modalities. This involves 
the treatment of cells with a fixed dose ratio of AICAR 
and ionizing radiation [34]. Combination indices of less 
than 1 were observed at all toxicity values (Figure 2C), 
confirming a synergistic interaction between AICAR and 
ionizing radiation in vitro. The enhancing effect of AICAR 
on radiation observed in PC3 cells in 2-dimensional 
clonogenic assays was confirmed in LNCaP cells using 
Figure 6: Clonogenic survival of PC3 cells after combinations of AICAR and X-rays with inhibitors of mTOR or FASN. 
Clonogenic assay of PC3 after administration of AICAR (0.5 mM) and (A) Everolimus (0.3 mM) or (B) C75 (25 µM), singly and in combination, 
with and without radiation (2 Gy X-rays). Clonogenic assay was carried out 24 h after simultaneous treatment. Data are means ± SEM, 
n = 3. *p < 0.05 and **p < 0.01.
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3-dimensional spheroid growth assays, although higher 
concentrations of AICAR were required to sensitize 
spheroids. The relative resistance of multicellular 
spheroids has previously been observed by us [20, 36] 
and is most likely due to differences in drug penetration 
and the microenvironment of the various layers within the 
spheroid [37]. When comparing assays in 2-dimensional 
cultures, results were comparable for both cell lines.
Although cells are most sensitive to ionizing 
radiation in the G2/M phase of cell cycle [38], the 
administration of AICAR as a single treatment did not 
induce cell cycle arrest and had no effect on cell cycle 
distribution in either PC3 or LNCaP cells. This may 
explain why there was no significant benefit in scheduling 
AICAR before x-irradiation. Simultaneous administration 
of both treatments was the most cytotoxic schedule. 
Cell cycle arrest was observed in the G2/M phase after 
irradiation of both cell lines.
Abnormalities in p53 are not as common in prostate 
cancer as they are in other cancers, and LNCaP and PC3 
cells differ in their p53 status, expressing wild type p53 
and non-functional p53, respectively [39]. Following 
irradiation, the observed cell cycle arrest of PC3 cells in 
the G2/M phase may occur through a p53-independent 
mechanism, such as through p53-independent p21 
activation as previously shown for ionizing radiation in 
the same cell line [9]. However, we observed that p21 
expression was not detected in PC3 cells in response to 
irradiation. The abrogation of radiation-induced cell cycle 
arrest by AICAR in both cell lines, using concentrations 
and timepoints shown to radiosensitize, indicates that this 
may be one mechanism whereby AMPK activation may 
lead to unrepaired DNA damage and mitotic catastrophe, 
resulting in cell death [40]. The G1 arrest observed in 
LNCaP cells, but not PC3 cells, 24 h after irradiation 
was most likely due to the presence of functional p53 in 
LNCaP, but not PC3, cells. The suppression of radiation-
induced G1 arrest by AICAR in LNCaP cells may be 
another mechanism contributing to radiosensitization in 
these cells.
Loss of phosphatase and tensin homologue (PTEN) 
is the most common mutation of a tumor suppressor gene 
in prostate cancer, and both cell lines used in this study 
have inactive PTEN [41]. PTEN is a negative regulator of 
the PI3K-Akt pathway and downstream mTOR signalling 
and its loss of function leads to dysregulation of this 
pathway, increasing proliferation, survival, resistance to 
therapy and altering metabolism [42]. Re-introduction of 
PTEN in PTEN-null prostate cancer or inhibition of the 
PI3K pathway also decreased expression of fatty acid 
synthase [43], demonstrating the importance of its role 
in prostate cancer. Radiation-induced activation of the 
PI3K/Akt/mTOR pathway may limit the effectiveness of 
radiotherapy and inhibition of this pro-survival pathway 
enhanced sensitivity to radiotherapy in glioblastoma and 
prostate cancer cells [44, 45].
It has been suggested that drugs which inhibit 
mTOR signalling may increase the efficacy of other 
chemotherapeutic agents [21]. We observed that the 
mTOR inhibitor everolimus enhanced the clonogenic 
killing activity of X-rays in PC3 cells. Sengupta et al. 
[46] demonstrated that the mTOR inhibitor rapamycin 
increased the anti-proliferative activity of AICAR 
in leukaemia cells. However, we observed that a 
combination of everolimus and AICAR induced only 
a slight, non-significant, increase in clonogenic killing 
activity compared to either agent alone. Moreover, the 
simultaneous administration of AICAR and everolimus 
did not enhance the radiosensitization caused by either 
drug alone. AMPK activation by AICAR suppresses the 
mTOR signalling pathway [47], leading to decreased 
proliferation and survival. Thus, it is possible that 
administration of AICAR alone is sufficient to abrogate 
the mTOR hyperactivity in PC3 cells caused by inactive 
PTEN, making addition of an mTOR inhibitor redundant.
AMPK phosphorylates and inactivates ACC [48], 
the most highly regulated enzyme in the fatty acid synthase 
pathway. We also observed the phosphorylation of ACC 
in response to AICAR at concentrations used in this 
study. Furthermore, metformin decreased FASN protein 
levels in breast cancer cells [49] and the FASN inhibitor 
orlistat up-regulated AMPK activity in lung cancer cells 
[50]. This demonstrates the critical role of fatty acid 
metabolism in cellular energy production and suggests an 
important interaction between AMPK and FASN. We have 
previously showed that the fatty acid synthase inhibitor 
C75 sensitized prostate cancer cells to ionizing radiation 
[20]. Although the potential use of C75 has been limited 
due to side effects of appetite suppression and weight 
loss [51], this may be overcome using enantiomers of 
C75 which retain anti-tumor and radiosensitizing activity 
in the absence of anorexia [35, 52]. We demonstrate 
here that C75 is able to enhance the clonogenic killing 
activity of AICAR. This suggests that combining agents 
which target two important pathways in prostate cancer 
carcinogenesis, lipogenesis and energy regulation, is a 
promising therapeutic approach. Furthermore, the triple 
combination of C75, AICAR and x-irradiation induced 
a level of clonogenic kill greater than the anticipated 
additive effect of any combination of two modalities. 
This indicates that drugs which target pathways which are 
dysregulated in aggressive cancers and are associated with 
altered metabolism, proliferation, and resistance to therapy 
can increase the efficacy of radiotherapy.
In conclusion, we have demonstrated that activation 
of AMPK using AICAR enhanced the clonogenic killing 
and spheroid growth delay effect of x-irradiation in 
prostate cancer cell lines. The interaction appeared to 
be synergistic and the mechanism of interaction may 
involve alterations in cell cycle regulation, regardless of 
the p53 status of the cells. Although this study suggests 
the potential use of activators of AMPK in combination 
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with radiotherapy of prostate cancer cells, AICAR has 
limited oral bioavailability [53]. Therefore, the use of 
novel AMPK activators with greater specificity and 
bioavailability are currently being developed [54]. 
Moreover, the radiosensitizing activity of AMPK 
activators may be most beneficial in the management 
of advanced disease where they can be combined with 
molecular targeted radiopharmaceuticals, such as those 
binding prostate specific membrane antigen (PSMA) [55].
MATERIALS AND METHODS
Reagents
All cell culture media and supplements were 
purchased from Life Technologies (UK), unless stated 
otherwise. AICAR was purchased from Santa Cruz 
Biotechnology (Germany). All other chemicals were 
from Sigma-Aldrich (UK). Stock solutions of AICAR 
were prepared in dimethyl sulfoxide (DMSO). Control 
treatments contained DMSO alone in culture medium.
Tissue culture
Human prostate cancer cell lines, PC3 and LNCaP, 
were obtained from American Type Culture Collection 
(Manassas, VA, USA) and were used in this study for 
less than 6 months after resuscitation. PC3 cells were 
maintained in F12K medium supplemented with 10% (v/v) 
fetal bovine serum (Labtech, UK), 2 mM L-glutamine, 
0.1 mM sodium pyruvate and 50 μg/ml gentamicin. 
LNCaP cells were maintained in RPMI 1640 medium 
supplemented with 10% (v/v) fetal bovine serum (Hyclone, 
ThermoFisher Scientific, UK), 1% (v/v) HEPES, 1% (v/v) 
D-glucose, 1 mM sodium pyruvate, 4 mM L-glutamine, 
50 μg/ml gentamicin.
MTT toxicity assay
MTT reduction was performed according to the 
method of Mosmann [56]. Cells were seeded in 96-well 
plates and incubated for 2 days to allow exponential 
phase growth. Cells were then washed with PBS and 
medium containing drug at the required concentration was 
added. After 24 h incubation, MTT was added to a final 
concentration of 0.5 mg/ml and cultures were incubated 
for 2 h. Cells were then solubilized with DMSO before 
measuring absorbance at 570 nm.
Clonogenic survival assay
PC3 cells were seeded in 25 cm2 flasks at 
105 cells/flask. When cultures were in exponential growth 
phase, medium was removed and replaced with fresh 
medium containing drug. Cells were then incubated 
for 24 h at 37° C in 5% CO2. For the determination 
of optimal sequencing of therapeutic agents, three 
different combination treatment schedules were assessed: 
(i) radiation and AICAR administered simultaneously, 
(ii) radiation administered 24 h before AICAR, (iii) radiation 
administered 24 h after AICAR. After treatment, cells were 
seeded for clonogenic survival assay as previously described 
[20, 35]. Cells were incubated at 37° C in 5% CO2 for 13 
days. Colonies were fixed in methanol, stained with crystal 
violet solution and colonies of at least 50 cells were counted. 
To assess the role of reactive oxygen species in AICAR-
induced cytotoxicity, cells were co-incubated with the 
antioxidant N-acetyl cysteine (NAC, 1 mM).
Cells were irradiated using an X-Strahl RS225 x-ray 
irradiator at a dose rate of 1.6 Gy per minute. The cytotoxic 
interaction between AICAR and x-radiation in vitro was 
assessed according to the method of Chou and Talalay 
[34], which is based on the median-effect principle. 
Briefly, clonogenic assay was carried out using a fixed 
dose ratio of drug to radiation, based on the concentrations 
required to kill 50% of clonogens (IC50) of each single 
agent, so that the proportional contribution of each agent 
in the mixtures was the same at all treatment intensities. 
The effectiveness of combinations was quantified by 
calculating a combination index (CI) at various levels of 
cytotoxicity. CI < 1, CI = 1 and CI > 1 indicate synergism, 
additivity and antagonism, respectively.
Multicellular spheroid growth assay
Multicellular tumor spheroids consisting of LNCaP 
cells were obtained using the liquid overlay technique [57]. 
Spheroids were initiated by inoculating cells into a plastic 
flask coated with 1% (w/v) agar. After 3 days, aliquots 
of spheroids were transferred to sterile plastic tubes and 
centrifuged at 12 × g for 3 min. Thereafter, spheroids were 
re-suspended in serum-free culture medium containing 
AICAR or irradiated. After treatment, spheroids of 
approximately 100 µm in diameter were transferred 
individually into agar-coated wells of 24-well plates, as 
previously described [58]. Individual spheroid growth 
was monitored twice per week for three weeks using an 
inverted phase-contrast microscope connected to an image 
acquisition system. Two perpendicular diameters, dmax 
and dmin, were measured using image analysis software 
(ImageJ) and the volume, V (μm3), was calculated using 
the formula: V = π × dmax × dmin² / 6. The area under the 
V/V0 versus time curve (AUC) was calculated for 
individual spheroids using trapezoidal approximation.
Cell cycle analysis
Following AICAR treatment for 6 or 24 h, LNCaP 
or PC3 cells were trypsinized, then washed twice with 
PBS. Cells were fixed by treatment with ice cold 70% 
(v/v) ethanol; then washed twice with PBS and re-
suspended in PBS containing propidium iodide (10 μg/ml) 
and RNase A (200 μg/ml). Cells were stained for 
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30 min before flow cytometric analysis using a FACSVerse 
analyser (BD Biosciences, UK). Data were analysed using 
FlowJo software.
Immunoblotting
Antibodies against β-actin were obtained from 
Abcam, UK. The antibody against p53 was obtained from 
Santa Cruz Biotechnology, Germany. Antibodies against 
p53 phosphorylated at serine 15 was obtained from New 
England Biolabs, UK. The antibody against p21 was 
obtained from BD Biosciences, UK. Antibody against 
phosphorylated acetyl Co-A was obtained from Merck, 
UK. Whole cellular protein extracts were resolved in 
reducing and denaturing conditions by sodium dodecyl 
sulphate polyacrylamide gel electrophoresis. Proteins 
were transferred on to polyvinylidene difluoride (PVDF) 
Immobilon-P membranes (Merck, UK). Membranes were 
blocked with 7.5% (w/v) milk for 2 h prior to incubation 
with the primary antibodies overnight at 4° C. Membranes 
were then washed and incubated at room temperature for 
1 h with horseradish peroxidase-conjugated secondary 
anti-mouse or anti-rabbit antibody (Santa Cruz 
Biotechnology, Germany) to enable chemiluminescent 
detection using ECL (ThermoFisher Scientific, UK).
Statistical analysis
Data are presented as means ± standard error 
of the mean (SEM), with the number of independent 
repetitions provided in the legend to each figure. Statistical 
significance was determined using Student’s t test. A 
P value < 0.05 was considered to be statistically significant 
and < 0.01 highly significant.
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